期刊文献+

解析瑞舒伐他汀抗动脉粥样硬化的临床价值和药理 被引量:8

下载PDF
导出
摘要 目的对瑞舒伐他汀抗动脉粥样硬化的临床应用价值及其药理作用进行分析。方法动脉粥样硬化患者76例,随机分为两组,对照组37例给予阿司匹林治疗,观察组39例给予瑞舒伐他汀治疗,对比两组治疗效果。结果两组患者治疗前颈动脉内膜中层厚度(IMT)、总胆固醇(TC)、三酰甘油(TG)及低密度脂蛋白胆固醇(LDL-C)差异均无统计学意义(P>0.05),治疗后均显著改善,且观察组改善情况显著优于对照组(P<0.05);两组患者治疗期间均无明显不良反应。结论瑞舒伐他汀抗动脉粥样硬化的效果显著,在动脉粥样硬化防治中应用价值较高,值得在临床中推广。
作者 朱莹 宋志红
出处 《中国实用医药》 2014年第30期135-136,共2页 China Practical Medicine
  • 相关文献

参考文献6

二级参考文献52

  • 1赵勇,王建春,孙慧,王传霞,李元堂,尹承华,张杰,邵建华.环氧化酶-2基因-765G>C多态性与老年代谢综合征患者阿司匹林抵抗无关[J].中国分子心脏病学杂志,2011,11(3):164-168. 被引量:4
  • 2申文祥,党瑜华,陈魁,黄琼.冠状动脉粥样硬化性心脏病患者血浆可溶性细胞间黏附分子-1和可溶性血管细胞黏附分子-1水平检测[J].郑州大学学报(医学版),2007,42(3):546-548. 被引量:11
  • 3Consensus Committee o~ the Ninth International Cerebral He- modynamie Symposium, Basic identification criteria of Doppler microembolic signals. Stroke, 1995,26 : 1123-1130.
  • 4Levy El, Mocco J, Samuelson RM, et al. Optimal treatment of carotid artery disease. J Am Coil Cardio, 2008,51 : 979-985.
  • 5FRANK P G,MARCEL Y L. Apolipoprotein A-I:structure-functionrelationships[J].Journal of Lipid Research,2000,(06):853-872.
  • 6PISCHON T,GIRMAN C J,SACKS F M. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men[J].CIRCULATION,2005,(22):3375-3383.
  • 7WALLDIUS G,JUNGNER I,HOLME I. High apolipoprotein B,low apolipoprotein A-I,and improvement in the prediction of fatal myocardial infarction (AMORIS study):a prospective study[J].The Lancet,2001,(9298):2026-2033.
  • 8Emerging Risk Factors Collaboration,DI ANGELANTONIO E,SARWAR N. Major lipids,apolipoproteins,and risk of vascular disease[J].Journal of the American Medical Association,2009,(18):1993-2000.
  • 9European Association For Cardiovascular Prevention & Rehabilitation,REINER Z,CATAPANO A L. ESC/EAS guidelines for the management of dyslipidaemias:The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J].EUROPEAN HEART JOURNAL,2011,(14):1769-1818.
  • 10LI N,LI S,YU C. Plasma Lp-PLA2 in acute coronary syndrome:association with major adverse cardiac events in a community-based cohort[J].Postgraduate Medicine,2010,(04):200-205.

共引文献173

同被引文献54

  • 1翁建新,靳立军,罗建方,张敏洲,岑俊莹.早期辛伐他汀干预对不稳定型心绞痛患者血清妊娠相关蛋白A和白细胞介素-6的影响[J].中国心血管杂志,2007,12(1):25-26. 被引量:3
  • 2中华医学会.临床诊疗指南:心血管内科分册[M].北京:人民卫生出版社’2009:1-5.
  • 3Eussen SR,Rompelberg CJ,Klungel OH,et al.Modeling approachto simulate reductions in LDL cholesterol levels after combinedintake of statins and phytosterols/-stanols in humans[J].Lipids Health Dis,2011,21(10):187.doi:10.1186/1476-511X-10-187.
  • 4Gargiulo G,Giugliano G,Brevetti L,et al.Use of statins in lower extremity artery disease:a review[J].BMC Surg,2012,12(Suppl 1):S15.
  • 5Qu HY,Xiao YW,Jiang GH,et al.Effect of atorvastatin versus rosuvastatin on levels of serum lipids,inflammatory markers and adiponectin in patients with hypercholesterolemia[J].Pharm Res,2009,26(4):958-964.
  • 6Andreas L,Tarek A,Michael B,et al.Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome[J].Eur J Heart,2006,27(24):2945-2955.
  • 7Resch U,Tatzher F,Budinshy A,et al.Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy[J].Br J Clin Pharmacol,2006,61(3):262-274.
  • 8Sato K, Nuki T, Gomita K, et all Statins reduce endothelial cell apop- tosis via inhibition of TRAIL expression on activated CIM T cells in a- cute coronary syndrome[ J. Atherosclerosis, 2010, 213 ( 1 ) :33 - 39.
  • 9Pekala J,Patkowska-Sokola B,Bodkowski R,et al. L-carnitine meta- bolic functions and meaning in humans life [ J ]. Current drug metabo- lism,2011,12 (7) : 667 -678.
  • 10Mingorance C, Rodriguez-Rodriguez R,Justo ML, et al. Pharmacologi- cal effects and clnical applications of propionyl-L-carnitine[ J ]. Nutri- tion reviews, 201 1,69 (5) : 279 - 290.

引证文献8

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部